Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironmentsShogo Kumagai, Hiroyoshi Nishikawa, Shohei Koyama et al.|Cancer Cell|2022Cited by 828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Hiroyoshi Nishikawa, Hitomi Nishinakamura et al.|Nature Immunology|2020Cited by 810
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 586
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapyYoshio Nakamura, Naoya Yamazaki, Shigehisa Kitano et al.|Oncotarget|2016Cited by 160